Pharmaceutical formulation containing heparin and endo-beta-gluc

Details Pharmaceutical formulation containing heparin and endo-beta-gluc Pharmaceutical formulation containing heparin and endo-beta-gluc

1992-11-09

1994-01-18

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

536 21, 435201, 435226, A61K 3754, C08B 3710, C12N 926, C12N 964

Patent

active

052798240

ABSTRACT:
A method of treating thrombosis with a pharmaceutical formulation comprising an endo-beta-glucuronidase, preferably leech-derived, heparin and a pharmacologically acceptable diluent, carrier or excipient which does not prevent the interaction between the heparin and the endo-beta-glucuronidase is disclosed. The formulation, which is disclosed, can also comprise a clot-lytic agent such as tissue plasminogen activator. Endo-beta-glucuronidase, unlike other hyaluronidases, has been found not to be inhibited by heparin.

REFERENCES:
patent: 2976212 (1961-03-01), Friedrich et al.
patent: 4390630 (1983-06-01), Sawyer et al.
patent: 4410531 (1983-10-01), Pope et al.
patent: 4568543 (1986-02-01), Borrelli et al.
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4820516 (1989-04-01), Sawyer et al.

Affiliated with

Also associated with

Rating

Pharmaceutical formulation containing heparin and endo-beta-gluc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation containing heparin and endo-beta-gluc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation containing heparin and endo-beta-gluc will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1134954